Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: Comparison of etest and agar screening methods

Journal of Clinical Microbiology

Volumn 49, Issue 6, 2011, Pages 2147-2150

  Riederer, K ^a   Shemes, S ^a   Chase, P ^a   Musta, A ^a   Mar, A ^a   Khatib, R ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

AGAR MEDIUM; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIUM DETECTION; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CULTURE MEDIUM; EPSILOMETER TEST; FEASIBILITY STUDY; INTERMETHOD COMPARISON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS;

AGAR; CULTURE MEDIA; HUMANS; MASS SCREENING; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NUCLEOPOLYHEDROVIRUS; STAPHYLOCOCCUS AUREUS;

EID: 79957484242     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01435-10     Document Type: Article

References (21)

1. Burnham, C.-A. D., C. J. Weber, and M. Dunn, Jr. 2010. Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus. J. Clin. Microbiol. 48:949-951.
2. Charles, P. G. P., P. B. Ward, P. D. R. Johnson, B. P. Howden, and L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
3. Chesneau, O., A. Morvan, and N. El Solh. 2000. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45:887-890.
4. Falagas, M. E., G. C. Makris, G. Dimopoulos, and D. K. Matthaiou. 2008. Heteroresistance: a concern of increasing clinical significance? Clin. Microbiol. Infect. 14:101-104.
5. Howden, B. P., J. K. Davies, P. D. R. Johnson, T. P. Stinear, and L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin. Microbiol. Rev. 23:99-139.
6. Khosrovaneh, A., et al. 2004. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 38:1328-1330.
7. Kosowska-Shick, K., et al. 2008. Incidence and characteristics of vancomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicob. Agents Chemother. 52:4510-4513.
8. Leonard, S. N., K. L. Rossi, K. L. Newton, and M. J. Rybak. 2009. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63:489-492.
9. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
10. Maor, Y., et al. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
11. Mohr, J. F., and B. E. Murray. 2007. Point: vancomycin is not obsolete for the treatment of infections caused by methicillin resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542.
12. Moise, P. A., A. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
13. Musta, A. C., et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
14. Rybak, M. J., et al. 2008. Characterization of vancomycin heteroresistant Staphylococcus aureus (hVISA) from the Detroit metropolitan area over a 22-year period (1986-2007). J. Clin. Microbiol. 46:2950-2954.
15. Swenson, J. M., et al. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47:2013-2017.
16. Soriano, A., et al. 2008. Influence of vancomycin minimal inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
17. Voss, A., et al. 2007. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptides intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann. Clin. Microbiol. Antimicrob. 6:9. doi:10.1186/1476-0711-6-9.
18. Walsh, T. R., et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
19. Wootton, M., et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
20. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
21. Yusof, A., et al. 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptides-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46:3042-3047.